Health & Aging Research in Companies

Neurochem

(www.neurochem.com)

Alzhemed™, Neurochem's leading candidate for the treatment of Alzheimer's disease, is in a North American Phase III clinical trial. The 20-month data showed that the large majority of mild AD patients responded well to treatment with Alz- hemed™ and continued to stabilize or improve based on a number of memory and functional as- sessment scales. (TSX-NRM)

Pro-Phage Inc.

Pro-Phage, a start-up company created in 1991 from a technology transfer from Hôpital Ste-Anne, has just received (February 2005) financing of CAN$ 2.4 million to start industrial production of its therapeutic food designed to allow dysphagia pa- tients to be fed normally. Many elderly are dying because they cannot eat enough. The patented technology, developed by Dr. Therèse Dufresne, CEO, is a process by which food texture is modi- fied and reconstituted to look and taste like the original. Pro-Phage produces 40 different menus, from milk to garden salad in aspic.

(http://sci.agr.ca/crda/tech/T2000_2_e.htm)

This document had been prepared by: Montréal International